Mutant Yeast Are Cranking Out Pharma’s Next Superdrug
March 10, 2016 | WIRED
Professor Gerngross's Adimab is using yeast to cure practically any disease for which a treatment is so ambitious doctors only dare to dream about it.
Student Spotlight: Sculptor Ham Sonnenfeld ’16
March 8, 2016 | The Dartmouth
A senior with a double major in engineering and studio art, F. Hambelton “Ham” Sonnenfeld ’16 has always enjoyed creating projects.
Ivy League Moves to Eliminate Tackling at Football Practices
March 1, 2016 | The New York Times
A new rule inspired by Dartmouth, where full-contact practices were eliminated by Coach "Buddy" Teevens '79. Instead, Dartmouth players practice tackling with the "Mobile Virtual Player."
Advance Transit to Launch Bus App
February 22, 2016 | Valley News
With the help of Dartmouth engineering students, the nonprofit transportation group plans to release its first smartphone app on Tuesday.
Adimab issues a challenge: Use new tech to build a rapid-response R&D platform for infectious diseases
February 18, 2016 | FierceBiotech
Adimab CEO Tillman Gerngross wants to challenge the way governments handle the R&D response to a viral outbreak.
5 Questions to Molly Herron (composer)
February 17, 2016 | I CARE IF YOU LISTEN
Brooklyn-based composer Molly Herron finds inspiration in both science and newly-invented instruments. Upcoming projects include collaborations with Dartmouth.
Busted knees and broken legs: Why ACL ski injuries have skyrocketed and what you can do about it
January 24, 2016 | Pique
Professor Rick Greenwald weighs in on the importance of bindings that can better release your foot during a twist.
Are DOT’s Tarmac Delay Fines Actually Making Delays Longer?
January 11, 2016 | TravelPulse
A study by Dartmouth and MIT has shown that passengers faced longer overall delays after the U.S. DOT’s 2010 tarmac delay rule was instituted.
Study: tarmac stranding rule creating more delays
January 11, 2016 | ConsumerAffairs
Dartmouth-MIT researchers say it's another example of unintended consequences.
Dementia Discovery Fund Chooses Alector for First Investment
January 7, 2016 | The Wall Street Journal
Alector, founded by Professor Tillman Gerngross, is developing drugs to address what its founders believe could be the root cause of dementia.